Imatinib Aurobindo (Imatinib)

Imatinib binds to the ATP‑binding site of BCR‑ABL, c‑KIT and PDGFR tyrosine kinases, locking them in an inactive state. This prevents downstream phosphorylation events that promote uncontrolled proliferation, thereby reducing tumor cell growth and inducing programmed cell death in affected tissues.

The exact dose and dosing schedule are determined by the prescribing physician based on the patient’s diagnosis, disease stage, renal and hepatic function, and other clinical factors. Healthcare providers tailor the regimen to achieve optimal therapeutic effect while minimizing adverse reactions.

Safety data for imatinib in pregnancy and lactation are limited, and the drug is generally avoided unless the potential benefit to the mother clearly outweighs any possible risk to the fetus or infant. Women of child‑bearing potential should discuss contraception and treatment options with their healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Imatinib was the first BCR‑ABL inhibitor approved and remains a cornerstone therapy for CML and GIST. Compared with newer agents, it has a well‑characterised safety profile and extensive clinical experience, though some newer inhibitors may offer activity against certain resistant mutations. Choice of therapy depends on disease characteristics, mutation status and physician judgment.

Imatinib Aurobindo should be stored at room temperature, below 25 °C, in its original container. Keep the product away from moisture, direct sunlight and extreme heat to maintain stability and potency throughout its shelf life.

The medication is taken orally, usually as a whole tablet swallowed with water. It can be taken with or without food, but patients should follow the specific instructions provided by their prescriber to ensure consistent absorption and therapeutic effect.

Serious adverse events include severe neutropenia or leukopenia, hepatotoxicity, cardiac dysfunction, life‑threatening bleeding, and rare pulmonary complications such as interstitial lung disease. Patients should be monitored regularly for blood counts, liver enzymes and cardiac function, and any alarming symptoms should prompt immediate medical evaluation.

Patients with known hypersensitivity to imatinib or any of its excipients should avoid the drug. Caution is also advised for individuals with severe hepatic impairment, uncontrolled cardiac disease, or those taking medications that strongly induce or inhibit CYP3A4 without appropriate monitoring.